82 related articles for article (PubMed ID: 17929306)
1. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
McHutchison JG; Bacon BR; Gordon SC; Lawitz E; Shiffman M; Afdhal NH; Jacobson IM; Muir A; Al-Adhami M; Morris ML; Lekstrom-Himes JA; Efler SM; Davis HL
Hepatology; 2007 Nov; 46(5):1341-9. PubMed ID: 17929306
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
Vicari AP; Schmalbach T; Lekstrom-Himes J; Morris ML; Al-Adhami MJ; Laframboise C; Leese P; Krieg AM; Efler SM; Davis HL
Antivir Ther; 2007; 12(5):741-51. PubMed ID: 17713157
[TBL] [Abstract][Full Text] [Related]
3. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.
Bergmann JF; de Bruijne J; Hotho DM; de Knegt RJ; Boonstra A; Weegink CJ; van Vliet AA; van de Wetering J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Janssen HL; Reesink HW
Aliment Pharmacol Ther; 2011 Aug; 34(4):443-53. PubMed ID: 21707679
[TBL] [Abstract][Full Text] [Related]
5. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
[TBL] [Abstract][Full Text] [Related]
7. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.
Horsmans Y; Berg T; Desager JP; Mueller T; Schott E; Fletcher SP; Steffy KR; Bauman LA; Kerr BM; Averett DR
Hepatology; 2005 Sep; 42(3):724-31. PubMed ID: 16116638
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of interferon gamma for chronic hepatitis C.
Soza A; Heller T; Ghany M; Lutchman G; Jake Liang T; Germain J; Hsu HH; Park Y; Hoofnagle JH
J Hepatol; 2005 Jul; 43(1):67-71. PubMed ID: 15913831
[TBL] [Abstract][Full Text] [Related]
10. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
Hotho DM; de Bruijne J; O'Farrell AM; Boyea T; Li J; Bracken M; Li X; Campbell D; Guler HP; Weegink CJ; Schinkel J; Molenkamp R; van de Wetering de Rooij J; van Vliet A; Janssen HL; de Knegt RJ; Reesink HW
Antivir Ther; 2012; 17(2):365-75. PubMed ID: 22293533
[TBL] [Abstract][Full Text] [Related]
12. Treatment of HCV infection by targeting microRNA.
Janssen HL; Reesink HW; Lawitz EJ; Zeuzem S; Rodriguez-Torres M; Patel K; van der Meer AJ; Patick AK; Chen A; Zhou Y; Persson R; King BD; Kauppinen S; Levin AA; Hodges MR
N Engl J Med; 2013 May; 368(18):1685-94. PubMed ID: 23534542
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C.
Chan HL; Ren H; Chow WC; Wee T;
Hepatology; 2007 Aug; 46(2):315-23. PubMed ID: 17654600
[TBL] [Abstract][Full Text] [Related]
14. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy.
Pockros PJ; Patel K; O'Brien C; Tong M; Smith C; Rustgi V; Carithers RL; McHutchison JG; Olek E; Debruin MF
Hepatology; 2003 Jun; 37(6):1368-74. PubMed ID: 12774016
[TBL] [Abstract][Full Text] [Related]
15. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
[TBL] [Abstract][Full Text] [Related]
16. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
Boonstra A; Liu BS; Groothuismink ZM; Bergmann JF; de Bruijne J; Hotho DM; Hansen BE; van Vliet AA; van de Wetering de Rooij J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Reesink HW; de Knegt RJ; Janssen HL
Antivir Ther; 2012; 17(4):657-67. PubMed ID: 22301364
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
Hoofnagle JH; Ghany MG; Kleiner DE; Doo E; Heller T; Promrat K; Ong J; Khokhar F; Soza A; Herion D; Park Y; Everhart JE; Liang TJ
Hepatology; 2003 Jul; 38(1):66-74. PubMed ID: 12829988
[TBL] [Abstract][Full Text] [Related]
18. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Wilfret DA; Walker J; Voitenleitner C; Baptiste-Brown S; Lovern M; Kim J; Adkison K; Shotwell B; Mathis A; Moss L; Lee D; Yu L; Gan J; Spaltenstein A
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):439-48. PubMed ID: 27129119
[TBL] [Abstract][Full Text] [Related]
20. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.
Hopkins S; DiMassimo B; Rusnak P; Heuman D; Lalezari J; Sluder A; Scorneaux B; Mosier S; Kowalczyk P; Ribeill Y; Baugh J; Gallay P
J Hepatol; 2012 Jul; 57(1):47-54. PubMed ID: 22425702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
